Dennis Fournogerakis on innovative commercial approaches for CAR T-cell therapies

Share on facebook
Share on twitter
Share on linkedin

Newer gene immunotherapies, such as CAR T-cell therapies, can provide life-saving treatments for patients with rare blood disorders. Associate Partner Dennis Fournogerakis describes in PM360 Magazine how manufacturers can overcome commercial challenges at launch and beyond to help treatment centers offer these cutting-edge therapies to patients who need it most.